The Lyme vaccine: A cautionary tale

Epidemiology and Infection

Volumn 135, Issue 1, 2007, Pages 1-8

  Nigrovic, Lise E ^a   Thompson, K M ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DIETHYLTOLUAMIDE; DOXYCYCLINE; INSECT REPELLENT; LYME DISEASE VACCINE; OUTER SURFACE PROTEIN A; PLACEBO;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTHRITIS; BORRELIA BURGDORFERI; CHILL; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DELAYED DIAGNOSIS; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG MARKETING; DRUG SAFETY; EARLY DIAGNOSIS; EDITORIAL; ENDEMIC DISEASE; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; IXODES; LAW SUIT; LYME DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIMARY PREVENTION; PROTECTIVE CLOTHING; RHEUMATIC DISEASE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TICK BITE; TICK BORNE DISEASE; TOOTH DISCOLORATION; VACCINATION;

ANIMALS; BORRELIA BURGDORFERI GROUP; DRUG INDUSTRY; HUMANS; LYME DISEASE; LYME DISEASE VACCINES; MASS MEDIA; PATIENT ACCEPTANCE OF HEALTH CARE; PUBLIC OPINION; TICKS; VACCINATION;

EID: 33751359282     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268806007096     Document Type: Editorial

References (42)

1. Burgdorfer W, et al. Lyme disease-a tick-borne spirochetosis? Science 1982; 216: 1317-1319.
2. Steere AC, et al. The spirochetal etiology of Lyme disease. New England Journal of Medicine 1983; 308: 733-740.
3. Anon. Summary of notifiable diseases - United States 2002. Morbidity and Mortality Weekly Report 2004; 51: 1-84.
4. Nadelman RB, Wormser GP. Lyme borreliosis. Lancet 1998; 352: 557-565.
5. Steere AC, et al. Asymptomatic infection with Borrelia burgdorferi. Clinical Infectious Diseases 2003; 37: 528-532.
6. Shadick NA, et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Annals of Internal Medicine 1999; 131: 919-926.
7. Nadelman RB, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Annals of Internal Medicine 1992; 117: 273-280.
8. Dattwyler RJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. New England Journal of Medicine 1997; 337: 289-294.
9. Hayes EB, Piesman J. How can we prevent Lyme disease? New England Journal of Medicine 2003; 348: 2424-2430.
10. Sood SK, et al. Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic. Journal of Infectious Diseases 1997; 175: 996-999.
11. Nadelman RB, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. New England Journal of Medicine 2001; 345: 79-84.
12. Nadelman RB, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. American Journal of Medicine 1996; 100: 502-508.
13. Wallman IS, Hilton HB. Teeth pigmented by tetracycline. Lancet 1962; 1: 827-829.
14. Shapiro ED. Doxycycline for tick bites - not for everyone. New England Journal of Medicine 2001; 345: 133-134.
15. Lochary ME, Lockhart PB, Williams Jr. WT. Doxycycline and staining of permanent teeth. Pediatric Infectious Diseases Journal 1998; 17: 429-431.
16. Mathiesen DA, et al. Genetic heterogeneity of Borrelia burgdorferi in the United States. Journal of Infectious Diseases 1997; 175: 98-107.
17. Lin T, et al. Genetic heterogeneity of Borrelia burgdorferi sensu lato in the southern United States based on restriction fragment length polymorphism and sequence analysis. Journal of Clinical Microbiology 2001; 39: 2500-2507.
18. Keller D, et al. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. Journal of the American Medical Association 1994; 271: 1764-1768.
19. Sigal LH, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. New England Journal of Medicine 1998; 339: 216-222.
20. Steere AC, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipo-protein A with adjuvant. Lyme Disease Vaccine Study Group. New England Journal of Medicine 1998; 339: 209-215.
21. Lyme Disease Foundation Inc. Lyme disease vaccine: Hype or hope? Press release (http://www.lyme.org/vaccine/vaccine.html). Accessed 21 January 2004.
22. Thanassi WT, Schoen RT. The Lyme disease vaccine: Conception, development, and implementation. Annals of Internal Medicine 2000; 132: 661-668.
23. Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerging Infectious Diseases 1999; 5: 321-328.
24. Anon. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommended Report 1999; 48 (RR-7): 1-25.
25. CDC. Rotashield (Rotavirus) vaccine and intussusception (http://www.cdc.gov/nip/issues/rota/rotaq&a.htm). Accessed 20 April 2004.
26. Zanardi LR, et al. Intussusception among recipients of rotavirus vaccine: Reports to the vaccine adverse event reporting system. Pediatrics 2001; 107: E97.
27. Murphy TV, et al. Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine 2001; 344: 564-572.
28. Kramarz P, et al. Population-based study of rotavirus vaccination and intussusception. Pediatric Infectious Diseases Journal 2001; 20: 410-416.
29. Lathrop SL, et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine 2002; 20: 1603-1608.
30. LYMErix® synopsis of phase 4 observational study (http://www.fda.gov/ ohrms/dockets/ac/01/briefing/3680b2_06.pdf). Accessed 23 January 2004.
31. Nocton JJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. New England Journal of Medicine 1994; 330: 229-234.
32. Gross DM, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703-706.
33. Steere AC, et al. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis and Rheumatism 2003; 48: 534-540.
34. Rose CD, Fawcett PT, Gibney KM. Arthritis following recombinant outer surface protein A vaccination for Lyme disease. Journal of Rheumatology 2001; 28: 2555-2557.
35. BioMedNet (Gateways & News). The bitter feud over LYMErix: Big pharma takes on the wrong little Osp (http://gateways.bmn.com/hmsbeagle/106/ notes/feature3). Accessed 23 January 2004.
36. The United States of America Food and Drug Administration. Center for biologics evaluation and research vaccines and related biologic products advisory panel. (http://www.fda.gov/ohrms/dockets/ac/01/transcripts/ 3680t2_01.pdf). Accessed 23 January 2004.
37. GSK Vaccines. Important News: LYMErix™ discontinued. (http://gskvaccines.com/vaccines/pages/offer_detail_public.jsp). Accessed 13 April 2004.
38. Abbott A. Lyme disease: Uphill struggle. Nature 2006; 439: 524-525.
39. Anon. When a vaccine is safe. Nature 2006; 439: 509.
40. Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. American Academy of Pediatrics. Pediatrics 1998; 102: 1483-1491.
41. Anon. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Reports. Recommended Report 1999; 48 (RR-2): 1-20.
42. Danovaro-Holliday MC, Wood AL, LeBaron CW. Rotavirus vaccine and the news media, 1987-2001. Journal of the American Medical Association 2002; 287: 1455-1462.